fnn interview transcripts fri 25th, page-2

Take home message,

Joel Spreadborough: Finally Stewart, tell us about some of EcoQuest’s other key potential commercial opportunities for Fiscal 2014?

Dr Stewart Washer: Well I think the nice thing is if you look at we’re doing right now a pre-money of around $20 million. Look we’re deliberately doing it low to leave a lot of upside on the table, I think we’ll get traction pretty quickly and you’ll see us start to come up near the other stem cell companies. Stem cell companies that are in the clinic or even pre-clinical, are in the hundreds of millions; of course Mesoblast (ASX:MSB) is $1.8 billion market cap. So we’ve got some good upside in terms of where we’re going.
I mean we’re not there to compete or replace other stem cell companies; we want them to succeed in their diseases. We’ve got a manufacturing technology which is very valuable with the Cymerus technology, which could compliment very well.